Israel Englander Biovie Inc. Transaction History

Millennium Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.53 - $1.89 $12,621 - $45,008	-23,814 Reduced 64.43%	13,148 $6,000
Q4 2023 Feb 14, 2024	SELL	$1.22 - $5.24 $363,262 - $1.56 Million	-297,756 Reduced 88.96%	36,962 $46,000
Q2 2023 Aug 14, 2023	BUY	$4.09 - $8.29 $1.23 Million - $2.49 Million	300,227 Added 870.45%	334,718 $1.44 Million
Q1 2023 May 15, 2023	SELL	$4.89 - $10.53 $448,603 - $966,011	-91,739 Reduced 72.68%	34,491 $279,000
Q4 2022 Feb 14, 2023	BUY	$3.86 - $42.0 $487,247 - $5.3 Million	126,230 New	126,230 $981,000

340K

Ticker BIVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,165,300
Market Cap $92M
Description
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.